FDA Mandates Eye Condition Warning on GLP-1 Receptor Agonist Labels

The U.S. FDA is requiring safety labeling changes for all GLP-1 receptor agonist medications to include a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a rare but serious eye condition that can cause acute, painless decreased vision, including permanent loss. This mandate requires drug manufacturers to add this information to the Warnings and Precautions section, advising patients to report sudden vision changes to healthcare professionals immediately.